URTI

Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update

Retrieved on: 
Wednesday, February 14, 2024
Investigational New Drug, Peripheral edema, Anemia, Gastroenteritis, Medicine, Periodic breathing, Leukopenia, Diarrhea, Quality of life, Cough, Dizziness, Deep vein thrombosis, Nausea, Vomiting, DVT, Common, Tremor, Back pain, Constipation, Safety, Dexamethasone, First grade, Lower respiratory tract infection, URTI, Bronchitis, Therapy, Fatigue, Bortezomib, Pharmacokinetics, Thrombocytopenia, Rash, Patient, Neutropenia, Acceleration, Multiple myeloma, RMOC, IND, Insomnia, Lenalidomide, Appetite, Abdominal pain, Weakness, Pharmaceutical industry

The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).

Key Points: 
  • The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).
  • Remarkably, the trial is progressing ahead of schedule and with the addition of RMOC is now projected to conclude enrollment by Q1/2024.
  • I’m excited about the potential opportunity STAR-LLD can bring to multiple myeloma patients.”
    Earlier last month, Starton disclosed preliminary trial findings regarding the safety and efficacy of STAR-LLD for multiple myeloma.
  • Notably, no hematologic toxicities greater than Grade 1 have been observed following up to 3 cycles of treatment thus far.

Starton Therapeutics Announces Initial Key Safety and Efficacy Signals with STAR-LLD in Patients with Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Wednesday, January 3, 2024
Quality of life, Leukopenia, URTI, Constipation, Lower respiratory tract infection, IND, Insomnia, CD8, Diarrhea, PD-1, DVT, Anemia, Gastroenteritis, Tremor, Fatigue, Common, CD4, Nausea, Multiple myeloma, Neutropenia, Abdominal pain, Therapy, Lenalidomide, Pharmacokinetics, Weakness, Dizziness, Thrombocytopenia, Cytotoxic T cell, Dexamethasone, Appetite, Periodic breathing, Bortezomib, Toxicity, Back pain, Patient, Safety, Peripheral edema, Deep vein thrombosis, Vomiting, Cough, Rash, Bronchitis

Remarkably, there were no hematologic toxicities greater than Grade 1 observed to date. Only a single drug-related adverse event was reported -- subcutaneous induration at the injection site which resolved within two weeks. In comparison, adverse events in these patients observed during a prior regimen containing Revlimid® included nausea, vomiting, deep vein thrombosis (DVT), upper respiratory tract infections (URTI), anemia, and fatigue. None of the more common side effects of lenalidomide (Revlimid®), which include diarrhea, fatigue, anemia, constipation, neutropenia, leukopenia, peripheral edema, insomnia, muscle cramp/spasms, abdominal pain, back pain, nausea, asthenia, pyrexia, bronchitis, nasopharyngitis, gastroenteritis, cough, rash, dyspnea, dizziness, decreased appetite, thrombocytopenia, and tremor, have been observed with STAR-LLD. Up to 30% of patients discontinue use of Revlimid® and roughly 70% dose reduce as a result of these adverse effects. These data suggest that STAR-LLD may prove to be superior in tolerability to oral Revlimid, expanding the number of patients that get the full Revlimid® benefit and improving quality of life.

Key Points: 
  • Patient acceptance of self-administration using the ambulatory pump for lenalidomide delivery has been confirmed in this study.
  • Remarkably, there were no hematologic toxicities greater than Grade 1 observed to date.
  • Only a single drug-related adverse event was reported -- subcutaneous induration at the injection site which resolved within two weeks.
  • Up to 30% of patients discontinue use of Revlimid® and roughly 70% dose reduce as a result of these adverse effects.

BeeNZ Is a Healthy Way to Restock the Pantry Before School Starts

Retrieved on: 
Thursday, August 31, 2023
Honey, Sneeze, Cleveland Clinic, Healthline, Parent, Esophagus, Cough, URTI, Common, Child, Water, Tea, Weather, Upper respiratory tract infection, Beenz.com, Health, Glass

FORT LAUDERDALE, Fla., Aug. 31, 2023 /PRNewswire/ -- It's back-to-school season, and that means colds are around the corner. While adults catch two or three colds per year, children are particularly susceptible to sniffles and sneezes, coming down with four or more colds each year on average. This coincides with the return to a group setting in educational facilities, along with more time spent indoors, in general, due to the colder weather.

Key Points: 
  • This coincides with the return to a group setting in educational facilities, along with more time spent indoors, in general, due to the colder weather.
  • Mānuka honey inherits these benefits and is known for its ability to help with unpleasant symptoms caused by colds.
  • "Mānuka honey is a powerful health and wellness tool," declares BeeNZ co-founder Julie Hayes.
  • "It is both a proactive and reactive way to maintain health during the cold and flu season."

Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis

Retrieved on: 
Saturday, January 14, 2023
Kimberley, FAAD, Common, URTI, IGA, Therapy, Icahn School of Medicine at Mount Sinai, Safety, Sinusitis, PDE4, MD, FDA, Irritation, Psoriasis, Urinary tract infection, Patient, Tachyphylaxis, AES, US Foods, Doctor of Philosophy, Mount Sinai, Cosmetics, Pharmaceutical industry, Dermatology

Roflumilast cream 0.3% (ZORYVE®) is a once-daily steroid free topical phosphodiesterase-4 (PDE4) inhibitor approved by the US Food and Drug Administration in July 2022.

Key Points: 
  • Roflumilast cream 0.3% (ZORYVE®) is a once-daily steroid free topical phosphodiesterase-4 (PDE4) inhibitor approved by the US Food and Drug Administration in July 2022.
  • Roflumilast cream was safe and very well tolerated, with the majority of adverse events (AEs) mild-to-moderate in severity.
  • Additional key findings following 52 weeks of treatment with roflumilast cream 0.3% include:
    IGA success was achieved by 35.3% of participants previously treated with roflumilast cream and 37.5% of roflumilast-naïve participants.
  • 1Cohort 1 not shown because I-IGA added as study amendment and numbers of patients evaluated are very small at each timepoint.

Insights on the Cough Syrup Global Market to 2027 - Increasing Prevalence of Upper Respiratory Tract Infection and Other Respiratory Disorders Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 4, 2023
Food, Beverage, Retail, URTI, Growth, Degenerative disease, COVID-19, Cough, Pharmacy, Honey, Upper respiratory tract infection, Prevalence, Tobacco, OTC, Air pollution, Agent handling, Mucus, Pharmaceutical industry

Cough syrup is a combination drug that is used to provide temporary relief from cough, common cold, hay fever and other respiratory allergies.

Key Points: 
  • Cough syrup is a combination drug that is used to provide temporary relief from cough, common cold, hay fever and other respiratory allergies.
  • The suppressants aid in alleviating the symptoms of dry cough by minimizing the activity of the cough reflex and reducing the urge to cough.
  • The increasing prevalence of upper respiratory tract infection (URTI) and other respiratory disorders across the globe is one of the key factors driving the growth of the market.
  • Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth.